England: HTA Body’s Income Hit By COVID-19
England’s health technology assessment body NICE did not recover costs for technology appraisals through fees thanks to the COVID-19 pandemic.
You may also be interested in...
Bayer’s “game-changing” histology-independent treatment is to be made available via the Cancer Drugs Fund.
Fees for appraisals that the health technology assessment body, NICE, will introduce in April could adversely impact companies with medicines for smaller indications, despite a bigger fee reduction for some manufacturers.
England’s Innovative Medicines Fund is aimed at providing earlier access to promising new treatments, including gene therapies, when further data is needed for routine commissioning.